Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PTPN1 | P18031 | 6/20 | 0.53 |
| ▸ | PTPN2 | P17706 | 1/20 | 0.53 |
| ▸ | PTPN6 | P29350 | 1/20 | 0.53 |
| ▸ | TSHR | P16473 | 1/20 | 0.51 |
| ▸ | ALDH1A1 | P00352 | 4/20 | 0.50 |
| ▸ | MAPT | P10636 | 3/20 | 0.50 |
| ▸ | CYP3A4 | P08684 | 2/20 | 0.50 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.50 |
| ▸ | GAA | P10253 | 1/20 | 0.50 |
| ▸ | ESR2 | Q92731 | 1/20 | 0.50 |
| ▸ | HNF4A | P41235 | 1/20 | 0.47 |
| ▸ | MEN1 | O00255 | 2/20 | 0.46 |
| ▸ | THRB | P10828 | 2/20 | 0.46 |
| ▸ | RECQL | P46063 | 2/20 | 0.46 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.46 |
| ▸ | TDP1 | Q9NUW8 | 2/20 | 0.46 |
| ▸ | USP2 | O75604 | 1/20 | 0.46 |
| ▸ | POLB | P06746 | 1/20 | 0.46 |
| ▸ | PKM | P14618 | 1/20 | 0.46 |
| ▸ | APEX1 | P27695 | 1/20 | 0.46 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL367880 | 0.87 | KDM4E (0.59) | PTPN1PTPN2PTPN6ALDH1A1MAPT | |
| SCHEMBL28589462 | 0.86 | PTPN1 (0.47) | PTPN1PTPN2PTPN6ALDH1A1MAPT | |
| SCHEMBL453471 | 0.85 | MAOB (0.50) | PTPN1ALDH1A1MAPTCYP3A4KDM4E | |
| SCHEMBL8961442 | 0.82 | PTPN1 (0.65) | PTPN1PTPN2PTPN6TSHRALDH1A1 | |
| SCHEMBL6772376 | 0.82 | TSHR (0.69) | PTPN1PTPN2PTPN6TSHRKDM4E | |
| SCHEMBL6441850 | 0.81 | PTPN1 (0.62) | PTPN1PTPN2PTPN6TSHRALDH1A1 | |
| SCHEMBL15796669 | 0.81 | TSHR (0.72) | PTPN1PTPN2PTPN6TSHRALDH1A1 | |
| SCHEMBL310681 | 0.81 | PTPN1 (0.58) | PTPN1PTPN2PTPN6TSHRALDH1A1 | |
| SCHEMBL17774718 | 0.80 | PTPN1 (0.71) | PTPN1PTPN2PTPN6TSHRALDH1A1 | |
| SCHEMBL16584765 | 0.80 | PLA2G2A (0.59) | PTPN1PTPN2PTPN6TSHRMAPT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 18 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-10336741-B2 | Substituted pyrrolidines as factor XIa inhibitors for the treatment thromboembolic diseases | ONO PHARMACEUTICAL CO., LTD. (JP) | 2019-07-02 | — | — | US | disclosed |
| US-20170137412-A1 | SUBSTITUTED PYRROLIDINES AS FACTOR XIA INHIBITORS FOR THE TREATMENT THROMBOEMBOLIC DISEASES | ONO PHARMACEUTICAL CO., LTD. (JP) | 2017-05-18 | — | — | US | disclosed |
| US-20120165520-A1 | PROCESS FOR THE SYNTHESIS OF PRODRUGS OF OPIOIDS | SHIRE LLC | 2012-06-28 | — | — | US | disclosed |
| US-20110190267-A1 | PRODRUGS OF OPIOIDS AND USES THEREOF | SHIRE PHARMACEUTICALS, INC. (US) | 2011-08-04 | — | — | US | disclosed |
| WO-2011083304-A1 | PRODRUGS OF OPIOIDS AND USES THEREOF | SHIRE LLC (US) | 2011-07-14 | — | — | WO | disclosed |
| US-6277880-B1 | ANTIBODY DIRECTED ENZYME PRODUG THERAPY | ZENECA LIMITED (GB) | 2001-08-21 | — | — | US | disclosed |
| US-5958971-A | PRODRUGS OF NITROGEN MUSTARD, AN ANTICARCINOGENIC AND TUMOR AGENT; ANTIBODY DIRECTED ENZYME PRODRUG THERAPY (ADEPT); BIOCHEMICAL CONJUGATION | ZENECA LIMITED (GB) | 1999-09-28 | — | — | US | disclosed |
| EP-0651740-B1 | AMINO ACID LINKED NITROGEN MUSTARD DERIVATIVES AND THEIR USE AS PRODRUGS IN THE TREATMENT OF TUMOURS | ZENECA LTD (GB) | 1998-10-21 | — | — | EP | disclosed |
| US-5714148-A | PRODRUGS WHICH ARE SUBSTRATES FOR CARBOXYPEPTIDASE G2 AND YIELD ACTIVE CYTOTOXIC DRUGS | ZENECA LIMITED (GB) | 1998-02-03 | — | — | US | disclosed |
| US-5660829-A | DEESTERIFYING COMPOUND TO FORM N-(4(N,N-BIS(2-CHLOROETHYL) AMINO)PHENOXYCARBONYL)-L-GLUTAMIC ACID-GAMMA-(3,5-DICARBOXY)ANILIDE | ZENECA LIMITED (GB) | 1997-08-26 | — | — | US | disclosed |
| US-5587161-A | TWO COMPONENT SYSTEM INCLUDING ANTIBODY OR ANTIGEN BINDING FRAGMENT CONJUGATED TO CARBOXYPEPTIDASE G ENZYME, COMPOUND CONVERTIBLE TO CYTOTOXIC DRUG UNDER INFLUENCE OF ENZYME | ZENECA LIMITED (GB) | 1996-12-24 | — | — | US | disclosed |
| EP-0651740-A1 | AMINO ACID LINKED NITROGEN MUSTARD DERIVATIVES AND THEIR USE AS PRODRUGS IN THE TREATMENT OF TUMOURS | ZENECA LIMITED (GB) | 1995-05-10 | — | — | EP | disclosed |
| US-5405990-A | For use in antibody directed enzyme prodrug therapy; cytotoxic parent nitrogen mustard; antitumor agents | ZENECA LIMITED (GB) | 1995-04-11 | — | — | US | disclosed |
| EP-0570507-A4 | ANTI-AGGREGATORY PEPTIDES CONTAINING AN AROMATIC ESTER OR AMIDE | SMITHKLINE BEECHAM CORP (US) | 1994-09-21 | — | — | EP | disclosed |
| WO-1994002450-A1 | AMINO ACID LINKED NITROGEN MUSTARD DERIVATIVES AND THEIR USE AS PRODRUGS IN THE TREATMENT OF TUMOURS | ZENECA LIMITED (GB) | 1994-02-03 | — | — | WO | disclosed |
| EP-0570507-A1 | ANTI-AGGREGATORY PEPTIDES CONTAINING AN AROMATIC ESTER OR AMIDE | SMITHKLINE BEECHAM CORPORATION (US) | 1993-11-24 | — | — | EP | disclosed |
| WO-1992013552-A1 | ANTI-AGGREGATORY PEPTIDES CONTAINING AN AROMATIC ESTER OR AMIDE | SMITHKLINE BEECHAM CORPORATION (US) | 1992-08-20 | — | — | WO | disclosed |
| US-4000297-A | GASTROENTERIC ACTIVITY | ROTTA RESEARCH LABORATORIUM S.P.A. (IT) | 1976-12-28 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20170137412-A1 | SUBSTITUTED PYRROLIDINES AS FACTOR XIA INHIBITORS FOR THE TREATMENT THROMBOEMBOLIC DISEASES | F11, F9, F10 | PTPN1 1123/4885PTPN2 1415/4885PTPN6 1673/4885 |
| US-10336741-B2 | Substituted pyrrolidines as factor XIa inhibitors for the treatment thromboembolic diseases | F11, F9, F10 | PTPN1 1123/4885PTPN2 1415/4885PTPN6 1673/4885 |
| US-20110190267-A1 | PRODRUGS OF OPIOIDS AND USES THEREOF | OPRK1, OPRL1, OPRM1 | PTPN1 3272/4885PTPN2 3544/4885PTPN6 3089/4885 |
| US-20120165520-A1 | PROCESS FOR THE SYNTHESIS OF PRODRUGS OF OPIOIDS | OPRM1, OPRK1, OPRD1 | PTPN1 2348/4885PTPN2 2912/4885PTPN6 1707/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.